Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for RA-Associated Interstitial Pneumonia
NCT00578565Phase 3Completed
- Sponsor
- Eric Matteson
- Start
- May 2007
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in rheumatoid arthritis-associated interstitial lung disease (RA-ILD), sponsored by Eric Matteson. Started May 2007; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis-associated interstitial lung disease (RA-ILD)
Beyond the preview
Go deeper on NCT00578565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578565.